Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EPS (Weighted Average and Diluted) (2023 - 2026)

Lexaria Bioscience's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.06 for Q1 2026.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.06 for Q1 2026, up 60.0% from a year ago — trailing twelve months through Feb 2026 was -$0.47 (up 20.34% YoY), and the annual figure for FY2025 was -$0.66, down 40.43%.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.06 at Lexaria Bioscience, up from -$0.07 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.18 in Q3 2023 to a low of -$0.21 in Q2 2025.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.13 (2023), against an average of -$0.1.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 182.68% in 2024, then skyrocketed 60.0% in 2026.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.13 in 2023, then decreased by 23.08% to -$0.16 in 2024, then surged by 56.25% to -$0.07 in 2025, then rose by 14.29% to -$0.06 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.06, -$0.07, and -$0.13 for Q1 2026, Q4 2025, and Q3 2025 respectively.